BCR/ABL Major (p210) breakpoints
Alternative name:
Philadelphia chromosome, BCR-ABL1 Major
Methodology
Molecular
Test Description and clinical significance
Genes
BCR/ABL1 (t(9;22) Major (p210) breakpoints
Disease:
Chronic myeloid leukemia (CML), B-cell lymphoblastic leukemia/lymphoma (B-ALL), and acute myeloid leukemia (AML).
A polymerase chain reaction that is recommended for patients with either chronic myelogenous/myeloid leukemia (CML), a hematopoietic stem cell disease, or acute lymphoblastic leukemia (ALL), an aggressive type of leukemia of either B- or T-lineage immature lymphoid cells. In CML, identification of BCR-ABL1 fusion genes is used for diagnosis and ongoing therapeutic monitoring.
Specimen Requirements
Collection:
3ml EDTA, citrate (ACD) or Heparinized whole blood or bone marrow aspirates are transported at room temperature, received with 96 hr, refrigerated are stable for a week from the date of collection, Extracted RNA; a minimum volume of 20 ?l at 100ng/?l
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Clotted peripheral blood or bone marrow. Peripheral blood or bone marrow older than a week. Leukophoresis products. Improperly labeled specimens. Improperly stored RNA.
Storage & Transport
Blood or bone marrow specimens should be kept at room temperature and preferably received within 96 hrs of drawing, Previously extracted RNA is acceptable if stored at appropriate temperature short term at -20oC (up to two weeks) or long term at -80oC and should be transported on dry ice.
CPT(s)
81206
New York Approved
YES
TAT
5 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
